Capotril

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Capotril

What is Capotril?

Capotril is a pharmaceutical medication classified as an angiotensin-converting enzyme (ACE) inhibitor. It is primarily utilized in the management of cardiovascular and renal conditions. The active ingredient in this medication is captopril, which was the first ACE inhibitor developed for clinical use.

Mechanism of Action

Capotril functions by interfering with the body's renin-angiotensin-aldosterone system (RAAS). Under normal physiological conditions, an enzyme converts a substance called angiotensin I into angiotensin II. Angiotensin II is a potent vasoconstrictor, meaning it causes blood vessels to narrow. It also promotes the release of hormones that increase salt and water retention.

By inhibiting the enzyme responsible for this conversion, Capotril leads to several physiological effects:

  • Vasodilation: Blood vessels relax and widen, which reduces the resistance against which the heart must pump.
  • Reduction in Blood Pressure: The relaxation of blood vessels leads to a decrease in systemic blood pressure.
  • Decreased Cardiac Workload: Because the vessels are more relaxed, the heart can circulate blood more efficiently.

Therapeutic Indications

Capotril is used in various clinical contexts involving the heart and kidneys. Its primary applications include:

  • Hypertension: Management of high blood pressure to help prevent long-term complications.
  • Heart Failure: Use in chronic heart failure management to improve heart function and reduce the strain on the cardiac muscle.
  • Post-Myocardial Infarction: Administered following a heart attack to improve survival rates and help maintain the structural integrity of the heart's left ventricle.
  • Diabetic Nephropathy: Used in patients with type 1 diabetes to manage kidney disease by reducing the pressure within the filtering units of the kidney.

Regulatory References

  1. Captopril: The First Orally Active ACE Inhibitor

What side effects are possible with Capotril?

Capotril: Possible Side Effects and Safety Information

This section outlines documented adverse reactions and safety considerations for Capotril (an ACE inhibitor), strictly based on governmental regulatory documents.

Serious and Clinically Significant Adverse Reactions

The most serious safety consideration is a Black Box Warning regarding Fetal Toxicity. Use during the second and third trimesters of pregnancy can cause injury and death to the developing fetus and is strictly contraindicated. Capotril must be discontinued immediately upon detection of pregnancy.

Another critical risk is Angioedema, a rapid and severe swelling of the face, lips, tongue, throat, or intestines. This reaction can be life-threatening due to airway obstruction and requires immediate medical attention and cessation of the drug. Other serious, though rare, reactions include Neutropenia (low white blood cell count), Renal Failure, and severe Symptomatic Hypotension.

Common Adverse Reactions

Commonly reported side effects include a persistent, non-productive dry cough, dizziness or lightheadedness, changes in the sense of taste (a metallic or salty flavor, or reduced taste sensitivity), and certain types of skin rash.

Population-Specific Safety and Limitations

Capotril is contraindicated in patients with a history of ACE inhibitor-related angioedema or when co-administered with Aliskiren in patients with diabetes. Caution is necessary for patients with impaired renal function or certain collagen vascular diseases, as these conditions can increase the risk of serious hematological complications like neutropenia. Close monitoring of blood pressure, kidney function, and blood cell counts is standard practice during treatment.

Overdose and Emergency Response

Capotril Overdose and when to Seek Help: Official Regulatory Information

This information describes the documented manifestations and regulator-mandated emergency actions for Captopril overdose, strictly based on government regulatory documents.


Overdose Scope

Component Official Regulatory Statement
Documented overdose presentations: Severe hypotension, shock, lethargy, and bradycardia. Other manifestations include electrolyte disturbance and the risk of renal failure.
Physiological systems affected: Cardiovascular and Renal systems.
Emergency-response statements: If hypotension occurs, the patient must be placed in the supine position. Fluids and sodium supplements must be administered immediately to correct volume deficits. Haemodialysis can be considered for clearance.
When immediate medical help is required: Immediate medical attention is required for any suspected overdose, especially if manifesting as severe hypotension or signs of shock.

Overdose Classifications (High-Level)

Classification Official Regulatory Basis
Severity classification: Potential for severe and life-threatening outcomes, specifically shock and renal failure.
Overdose-context constraints: Management is symptomatic and supportive because no specific antidote is known. Atropine or cardiac pacing may be required for severe bradycardia.

The overdose profile is defined by the risk of Profound Circulatory Collapse leading to Acute Organ System Compromise. The required help-seeking conditions are dictated by the onset of these severe manifestations, which in turn mandate specific, regulator-documented, immediate interventions like volume expansion and the consideration of haemodialysis for drug clearance. Infants, especially newborns, may be more susceptible to adverse haemodynamic effects.

Therapeutic Uses of Capotril

Capotril is a therapeutic option indicated for the management of several significant cardiovascular conditions. It is commonly prescribed to support the reduction of high blood pressure (hypertension), which can contribute to mitigating overall cardiovascular strain. For patients with chronic heart failure, Capotril may contribute to the improvement of symptom domains, potentially allowing for better functional capacity. The medication is also utilized to provide support following a myocardial infarction (heart attack). Finally, it is used in patients with certain forms of diabetic kidney disease to help preserve kidney function over time.


Quick Fact: Relief for Blood Pressure

Capotril may support the maintenance of blood pressure within a target range, helping to manage a key risk factor for other cardiovascular issues.


Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Capotril — Official Regulatory Information

Capotril (Captopril) eligibility is strictly defined by regulatory documents based on patient conditions and demographics.


Populations for Whom Use is Contraindicated

Use is officially prohibited for patients with a history of angioedema related to any ACE inhibitor and for those in the second or third trimesters of pregnancy. Captopril is also contraindicated with concomitant use of aliskiren in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min), or within 36 hours of taking Sacubitril/Valsartan.

Age-Related and Condition-Specific Eligibility Rules

  • Adults: Established use for hypertension, heart failure, post-myocardial infarction, and diabetic nephropathy.
  • Pediatrics: Use in children and adolescents is not fully established and must be initiated under close medical supervision.
  • Elderly Patients: Therapy initiation requires considering a lower starting dose due to the higher likelihood of reduced organ function.
  • Impaired Renal Function: Patients with this condition require a reduced initial dosage or an increased dose interval to prevent drug accumulation. Use is restricted for hypertensives with collagen vascular disease and kidney impairment, reserved for those who failed other treatments.
  • Pregnancy/Lactation: Use is contraindicated in later pregnancy and not recommended in early pregnancy or for mothers breastfeeding preterm/newborn infants.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The regulatory interaction profile for Capotril (Captopril) is defined by pharmacodynamic constraints and specific timing requirements, centering on dual cardiovascular inhibition, potassium-level modification, and pharmacokinetic alteration.

Formal Contraindications and Restrictions

Co-administration with the Neprilysin Inhibitor Sacubitril/Valsartan is formally prohibited due to a significant risk of angioedema, requiring a mandatory 36-hour separation rule when switching therapy. The combination with Aliskiren is contraindicated specifically in patients with diabetes mellitus or existing renal impairment (GFR < 60 ml/min/1.73 m^2).

Pharmacodynamic and Exposure Effects

Interactions include an increased risk of hyperkalemia when Capotril is co-administered with Potassium-Sparing Diuretics or Potassium Supplements. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause a loss of the antihypertensive effect and increased risk of renal compromise; this risk is heightened in elderly, volume-depleted, or renally compromised patients. Co-administration with Lithium increases serum concentrations of lithium due to reduced clearance, raising the risk of toxicity.

A pharmacokinetic interaction with food is officially documented: ingestion reduces Capotril absorption by 25-40%. This requires the official administration rule to take Capotril one hour before a meal. These documented constraints mandate necessary adjustments to concomitant therapy.

Mechanism of Action

How Capotril Works

Capotril (Captopril) exerts its pharmacodynamic effect primarily as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE), a zinc metallopeptidase integral to the Renin-Angiotensin-Aldosterone System (RAAS).

By occupying the active site of ACE, Capotril prevents the enzyme from converting Angiotensin I into the vasoconstrictor Angiotensin II. This inhibition leads to a systemic decrease in circulating Angiotensin II levels, initiating a cascade that results in arterial and venous vasodilation and a reduction in Aldosterone secretion from the adrenal cortex. The resultant physiological effect is the relaxation of vascular smooth muscle and decreased fluid and sodium reabsorption in the distal nephron, which modifies volume-regulatory and vasoconstrictive responses.

Simultaneously, ACE functions as Kininase II, an enzyme that degrades the endogenous vasodilator bradykinin. Inhibition of ACE prevents bradykinin breakdown, leading to its localized accumulation. This increase enhances the bradykinin-mediated vasodilatory signaling, which complements the Angiotensin II reduction in influencing overall vascular tone.

Dosage and Administration Information

Capotril (Captopril) is administered exclusively by the oral route, primarily as a scored tablet. The critical administration instruction is to take the dose on an empty stomach, specifically one hour before any meal, as the presence of food significantly reduces the absorption of the active ingredient. The maintenance regimen typically requires the total daily dose to be divided and taken two or three times per day.

The official usage protocol involves starting with a low initial dose, such as 6.25 mg or 12.5 mg, which is then adjusted incrementally based on patient response. This controlled process of titration must be carried out at intervals of at least one to two weeks before any dose increase is made.

For specific patient populations, the official usage protocol mandates adjustments. Patients with impaired renal function require a lower initial dosage, with specific maximum daily doses linked to the measured creatinine clearance. Similarly, a lower starting dose (e.g., 6.25 mg twice daily) is generally considered for older adults.

If a dose is missed, the instruction is to take it as soon as it is remembered. However, if it is near the time for the next scheduled dose, the missed dose must be skipped entirely; the official guidance is not to take a double dose. The initiation of Capotril treatment for conditions like heart failure requires that the starting doses be administered under close medical supervision.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Capotril

Evidence for Use in High Blood Pressure (Hypertension)

Capotril was studied for the treatment of high blood pressure in Randomized Controlled Trials (RCTs) and long-term observational studies. Research focused on the measured changes in systolic and diastolic blood pressure readings in adults. Short-term trials reported measured changes, and longer-term studies described patterns of measured stability in blood pressure readings over several years in some patient cohorts. However, comparative evidence is lacking when assessed against many of the more recently developed blood pressure medications available today.


Evidence for Use in Chronic Heart Failure

The research base is built on large-scale, placebo-controlled Randomized Controlled Trials (RCTs). These studies monitored endpoints such as all-cause mortality (survival rates) and the frequency of hospitalization for heart failure exacerbations. The core findings describe patterns observed in the studies, noting differences in hospitalization rates and differences in long-term survival curves for the group receiving Captopril when compared to the placebo group. Evidence is limited for heart failure with preserved ejection fraction, as the main research focused on cohorts with reduced heart function.


Evidence for Use Following a Heart Attack (Myocardial Infarction)

Research exploring this area includes long-term Randomized, Placebo-Controlled Trials that enrolled adults shortly after a heart attack who exhibited left ventricular dysfunction. Trials described differences in the reporting of cardiac death and differences in overall mortality rates in the Captopril cohorts compared to the placebo groups over observation periods of several years.


Evidence for Use in Diabetic Kidney Disease (Diabetic Nephropathy)

Capotril was evaluated for the treatment of diabetic kidney disease in controlled clinical trials. Researchers monitored changes in proteinuria (protein in the urine) levels and the rate of decline in kidney function over time. Research reported differences in the rate of kidney function progression and measured differences in the level of urinary protein excretion when comparing the observed groups.


Summary of Research Gaps

While major trials have established group patterns, research does not determine whether an individual will respond similarly. Key areas where certainty remains low include: Follow-up durations were limited in some studies, meaning full long-term effects are not fully established; and subgroup findings are uncertain for many less-common patient cohorts.

Frequently Asked Questions (FAQ)

Common questions about Capotril (FAQ)


Q: How quickly should I expect Capotril to start working and what is the typical time frame for its full effect?

Official product information states that a reduction in blood pressure is often observed within 60 to 90 minutes of the first dose. However, achieving the maximum or full therapeutic benefit of a specific dose may require several weeks of consistent administration, as is typical for medications that require dose adjustment.


Q: Does Capotril affect liver function?

Official safety information includes warnings that Capotril has been associated with rare but serious adverse reactions involving the liver, such as elevated liver enzymes and jaundice. Caution is generally advised for patients with pre-existing impaired hepatic function, and discussion of medical history with a healthcare provider is noted.


Q: How long does Capotril stay in your system after stopping it?

According to pharmacokinetic data in official regulatory documents, the elimination half-life of Capotril is generally reported to be approximately 2 to 3 hours. This half-life is the time it takes for half of the drug's active ingredient to be naturally removed from the body.


Q: What should I do if a side effect of Capotril is bothersome?

Official patient guidance advises that if a common side effect becomes severe or bothersome and does not resolve, official guidance suggests contacting a healthcare provider. It is important to seek immediate medical attention if you experience signs of a serious reaction, such as swelling of the face, lips, or difficulty breathing.


Q: Are there known interactions between Capotril and alcohol?

Official patient guidance notes that alcohol may cause an additive effect in lowering blood pressure. The possibility of increased risk for dizziness, fainting, or changes in pulse/heart rate is noted, particularly during the initiation of therapy.


Q: Is Capotril a blood thinner?

No, Capotril is not classified as a blood thinner (an anticoagulant or anti-platelet medicine). It belongs to the essential drug class known as Angiotensin-Converting Enzyme (ACE) Inhibitors, which work by relaxing blood vessels to help stabilize cardiovascular function.


Q: Does Capotril cause weight gain or loss?

Official adverse reaction data includes rare reports of weight loss and loss of appetite. However, unexplained or rapid weight gain is noted in connection with potential kidney problems, and such a change is noted as a signal that may require prompt medical review.


Q: Are there any known issues with stopping Capotril suddenly?

Official guidance states that patients should consult a healthcare provider before discontinuing the medication. Studies on cessation noted a gradual return of blood pressure consistent with the loss of the medication's effect, and professional medical supervision is always required before discontinuing therapy.


Q: Does Capotril have any warnings about long-term use?

Official documents indicate that close monitoring of kidney function and blood cell counts is standard practice during long-term use. This monitoring is standard practice due to the potential for rare complications in some patient groups, such as a low white blood cell count (neutropenia).


Q: What is the difference between Capotril and other similar medicines?

According to official sources, Capotril is historically significant as the first orally effective medicine in the Angiotensin-Converting Enzyme (ACE) inhibitor class. It is also noted that Capotril is active immediately upon absorption, a feature that distinguishes it from some other medicines in its class that require activation by the liver (known as a 'prodrug').


Q: Does Capotril interact with common vitamins or supplements?

Official product information specifically warns against taking potassium supplements, including salt substitutes that contain potassium, because this can lead to dangerously high potassium levels in the blood. Patients are generally advised to inform their healthcare provider to review potential interactions.


Q: Is it safe to use Capotril if I have a history of allergies?

According to regulatory guidelines, Capotril is formally prohibited (contraindicated) if you have a history of angioedema (a type of rapid, severe swelling) related to any ACE inhibitor medicine. While a general history of allergies does not prohibit use, discussion of any allergy history with a prescribing provider is generally noted as a precaution.


Q: Do I need to change my diet while taking Capotril?

Official regulatory information requires that Capotril be taken one hour before a meal because food interferes with its absorption. Furthermore, the use of salt substitutes or potassium supplements is advised against to manage the risk of developing hyperkalemia (high potassium levels).


Q: Are there any specific foods to avoid when taking Capotril?

Official patient guidance specifically warns against the use of potassium supplements and salt substitutes containing potassium due to the risk of hyperkalemia. While specific foods are not prohibited, discussion of overall dietary potassium intake with a healthcare professional is generally suggested.


Q: Is Capotril linked to any major drug recalls?

Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), are responsible for maintaining public databases of drug recalls and safety alerts. These resources are updated continuously, and patients are advised to consult the official regulatory websites for the most current safety status of any medication they are taking.


Q: Where can I find the official regulatory information about Capotril?

Official regulatory information is made publicly available by government health bodies, including the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) MedlinePlus. This information can also be found in the manufacturer's official Summary of Product Characteristics (SmPC), which is available through regulatory portals.

How should Capotril be stored and disposed of?

How to Store and Dispose of Captopril (Capotril)

Captopril tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), and must be kept from freezing.

Storage Requirements

  • Protection: Store the medication away from excess heat, light, and moisture.
  • Container: Keep Captopril in the container it came in, ensuring it is tightly closed.
  • Child Safety: The product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Captopril must be disposed of according to local regulations. Utilize drug take-back programs when available. The medication should not be flushed down the toilet or poured into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Capotril found in:

A-Z Index: